Catch up on 5 melanoma and skin cancer readouts from ESMO 2026, including NADINA, OptimUM-01, OptimUM-09, C-POST, and KEYNOTE-630.
|Videos|June 6, 2018
Newer Targeted Approaches in Medullary Thyroid Cancer
Author(s)Manisha Shah, MD
In this video, Dr. Manisha Shah highlights new and emerging targeted therapies for medullary thyroid cancer, including research presented at ASCO 2018.
Advertisement
In this video, Dr. Manisha Shah highlights new and emerging targeted therapies for medullary thyroid cancer, including research presented at ASCO 2018.
Advertisement
Related to this article
ESMO 2026 posters showed durable EV-302 benefit in older and comorbid populations plus persistent early mortality in metastatic urothelial carcinoma.
A post hoc ReFocus analysis found prior immune checkpoint inhibitor exposure raised the risk of mucocutaneous AEs with lirafugratinib.
Data from the real-world CEMI-LUNG evaluating cemiplimab in advanced NSCLC were consistent with reports from the EMPOWER-Lung1 study.
A cisplatin-free pembrolizumab regimen yielded 65.1% laryngectomy-free survival rate at 2 years in SMART-KEY, missing significance vs historical controls.
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
Risvutatug rezetecan cut the risk of progression or death by 67% vs gemcitabine/docetaxel in heavily pretreated R/R osteosarcoma in ARTEMIS-011.
Two-year MANEUVER data show durable, deepening responses and sustained gains in pain, stiffness, and function with pimicotinib in TGCT.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Receives BLA for Etentamig in Relapsed/Refractory Multiple Myeloma
2
Elranatamab Improves PFS vs Standard Regimens in R/R Multiple Myeloma
3
Risvutatug Rezetecan Improves PFS in Relapsed/Refractory Osteosarcoma
4
Cisplatin-Free Pembrolizumab Regimen Misses Primary End Point in SMART-KEY
5